Legal & General Group
INO icon

Legal & General Group’s Inovio Pharmaceuticals INO Stock Holding History

Legal & General Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,196
Closed -$3.58K – 3473
2025
Q1 		$3.58K Hold
2,196
– – ﹤0.01% 3318
2024
Q4 		$4.02K Hold
2,196
– – ﹤0.01% 3355
2024
Q3 		$12.7K Hold
2,196
– – ﹤0.01% 3217
2024
Q2 		$17.7K Buy
+2,196
New +$23.1K ﹤0.01% 3072
2023
Q2 		– Sell
-4,250
Closed -$41.8K – 3460
2023
Q1 		$41.8K Sell
4,250
-4,465
-51% -$76.1K ﹤0.01% 2906
2022
Q4 		$163K Buy
8,715
+896
+11% +$20.3K ﹤0.01% 2688
2022
Q3 		$162K Sell
7,819
-5,935
-43% -$152K ﹤0.01% 2695
2022
Q2 		$286K Buy
13,754
+359
+3% +$10.1K ﹤0.01% 2514
2022
Q1 		$577K Hold
13,395
– – ﹤0.01% 2357
2021
Q4 		$802K Hold
13,395
– – ﹤0.01% 2290
2021
Q3 		$1.15M Buy
13,395
+3,405
+34% +$342K ﹤0.01% 2209
2021
Q2 		$1.11M Sell
9,990
-381
-4% -$36.6K ﹤0.01% 2187
2021
Q1 		$1.15M Buy
10,371
+2,328
+29% +$306K ﹤0.01% 2154
2020
Q4 		$854K Sell
8,043
-14
-0.2% -$1.86K ﹤0.01% 2156
2020
Q3 		$1.12M Buy
8,057
+4,408
+121% +$919K ﹤0.01% 1988
2020
Q2 		$1.18M Buy
3,649
+1,862
+104% +$299K ﹤0.01% 1927
2020
Q1 		$159K Sell
1,787
-410
-19% -$25.3K ﹤0.01% 2318
2019
Q4 		$87K Buy
2,197
+80
+4% +$2.41K ﹤0.01% 2637
2019
Q3 		$52K Buy
2,117
+497
+31% +$15.1K ﹤0.01% 2719
2019
Q2 		$57K Buy
1,620
+265
+20% +$10.5K ﹤0.01% 2719
2019
Q1 		$60K Buy
1,355
+86
+7% +$4.33K ﹤0.01% 2648
2018
Q4 		$61K Buy
1,269
+196
+18% +$11.9K ﹤0.01% 2622
2018
Q3 		$72K Hold
1,073
– – ﹤0.01% 2603
2018
Q2 		$51K Sell
1,073
-162
-13% -$8.94K ﹤0.01% 2734
2018
Q1 		$70K Sell
1,235
-508
-29% -$27.5K ﹤0.01% 2608
2017
Q4 		$86K Hold
1,743
– – ﹤0.01% 2659
2017
Q3 		$132K Buy
1,743
+398
+30% +$29.6K ﹤0.01% 2495
2017
Q2 		$127K Hold
1,345
– – ﹤0.01% 2484
2017
Q1 		$106K Sell
1,345
-14
-1% -$1.11K ﹤0.01% 2506
2016
Q4 		$113K Buy
1,359
+718
+112% +$64.9K ﹤0.01% 2489
2016
Q3 		$71K Sell
641
-459
-42% -$50.7K ﹤0.01% 2361
2016
Q2 		$121K Hold
1,100
– – ﹤0.01% 1993
2016
Q1 		$119K Buy
1,100
+100
+10% +$7.72K ﹤0.01% 1954
2015
Q4 		$83K Hold
1,000
– – ﹤0.01% 2190
2015
Q3 		$70K Buy
1,000
+86
+9% +$7.49K ﹤0.01% 2252
2015
Q2 		$88K Buy
914
+176
+24% +$18.8K ﹤0.01% 2211
2015
Q1 		$72K Hold
738
– – ﹤0.01% 2266
2014
Q4 		$82K Hold
738
– – ﹤0.01% 2114
2014
Q3 		$87K Buy
+738
New +$92K ﹤0.01% 1983

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Legal & General Group's INO Position: Q2 2025 in Review

Legal & General Group sold out of Inovio Pharmaceuticals (INO) in Q2 2025, closing a stake of 2,196 shares — an estimated $3.58K sold.

Legal & General Group first reported a position in INO in Q3 2014 and held it in 39 quarters. The position peaked at $1.18M in Q2 2020. 103 funds tracked by Wall St. Rank hold INO as of Q2 2025.

  • Legal & General Group reported no remaining Inovio Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 2,196 Inovio Pharmaceuticals shares in Q2 2025, an estimated $3.58K.
  • Legal & General Group first reported a position in Inovio Pharmaceuticals in Q3 2014 and held it in 39 quarters.
  • Legal & General Group's Inovio Pharmaceuticals position peaked at $1.18M in Q2 2020.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.